

May 17, 2024

Via E-Mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Report Pursuant to 18 V.S.A. §4637(b)

To the Office of Attorney General:

On May 17, 2024 Delcath Systems, Inc. ("Delcath") submitted notice of the following FDA approved:

<b>NDC</b>	<b>Product Name</b>	<b>Product Description</b>
75833-601-02	Hepzato	Hepzato Kit (melphalan) for Injection/Hepatic Delivery System (HDS) - 62 mm

As per 18 V.S.A. §4637(c), Delcath is now providing additional product information for the aforementioned new drugs.

Marketing and Pricing Plans

Plan not made public

Estimated Patient Volume

320

Breakthrough Therapy/Priority Review

Ultra orphan drug designation for the treatment of metastatic uveal melanoma for treatment of the liver metastases

Acquisition Date and Price

This is not applicable.